ADC Therapeutics SA held its annual general meeting of shareholders on June 3, 2025. Shareholders approved the management report, annual financial statements, and consolidated financial statements for the year ended December 31, 2024. The members of the board of directors and the executive committee were discharged from liability for the year ended December 31, 2024. The net loss for the year ended December 31, 2024, will be carried forward. Several directors were elected or reelected, including Ron Squarer, Robert Azelby, Jean-Pierre Bizzari, Peter Hug, Ameet Mallik, Viviane Monges, Tyrell Rivers, Victor Sandor, and Timothy Coughlin.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。